Harman Patil (Editor)

Elafibranor

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
ATC code  None
Synonyms  GFT505, SureCN815512
PubChem CID  9864881
Molar mass  384.489 g/mol
Legal status  Investigational
CAS Number  923978-27-2
ChemSpider  8040573
Elafibranor wwwgenfitcomwpcontentuploads201403coverre

Elafibranor (INN, code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).

Contents

Elafibranor is a dual PPARα/δ agonist.

Clinical studies

Administered to over 800 patients and healthy volunteers to date, elafibranor has demonstrated:

  • beneficial properties for non-alcoholic steatohepatitis (NASH)
  • improvement of insulin sensitivity and glucose homeostasis
  • Phase 2b (GOLDEN) results were published online in Gastroenterology in February 2016 and will be fully available in the paper version in May 2016.

    As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress.

    Pre-clinical studies

    Efficacy on histological NASH parameters (steatosis, inflammation, fibrosis) in animal disease models — anti-fibrotic activities.

    The absence of safety concern has been confirmed in a full toxicological package up to 2-year carcinogenicity studies and cardiac studies (in mice).

    References

    Elafibranor Wikipedia


    Similar Topics
    Moby Dick (1930 film)
    Sarvadaman D Banerjee
    Abdul Sattar Murad
    Topics